NTRA Stock Price Today (July 2026) — Natera, Inc. Analysis & Key Metrics 2026-07-17
Natera, Inc. (NTRA) is trading at $271.39, up 0.58% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $262.67 (-3.2% upside).
- Volatility remains elevated (29.64% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (38.80% YoY) alongside significant competitive pressures.
NTRA Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Natera, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $38.03B
P/E Ratio
Forward P/E: -1332.54
Revenue Growth
Year over Year
Analyst Target
+-3.2% upside potential
Key Investor Questions About NTRA
What investors need to know before buying
Based on current market data, NTRA presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 57.31)
- Fundamentals say: Caution warranted (high leverage concerns)
NTRA's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NTRA investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $240.08M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, NTRA stock traded between $131.81 and $279.42—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 29.64% annualized volatility and β=1.23, the stock exhibits high sensitivity to market moves—making NTRA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Natera (NASDAQ:NTRA) and its peers.
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves.
It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months.
Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group
Cathie Wood Unveils Major Portfolio Reset With SpaceX, Meta Buys and AMD Cuts
Did EU Class C Status for Signatera Reshape Natera’s (NTRA) Long-Term Diagnostics Strategy?
Natera recently reported that its Signatera molecular residual disease test secured Class C certification under the European Union’s In Vitro Diagnostic Regulation, enabling continued availability across multiple cancer indications beyond the 2028 transition deadline. This certification marks a meaningful strengthening of Signatera’s regulatory standing in one of the world’s most stringent diagnostic markets, with potential implications for clinical trial adoption and broader clinical use in...
Natera (NTRA) Secures EU Certification, Is The Upside Already Priced In?
Natera (NTRA) has secured Class C certification for its Signatera platform under the European Union’s In Vitro Diagnostic Regulation, a key regulatory milestone that supports continued access to the test in Europe beyond 2028. See our latest analysis for Natera. The IVDR milestone comes on the heels of fresh clinical data for Signatera, a new partnership with Aveta Biomics and a board change, and the stock has reacted strongly, with a 30 day share price return of 26.49% and a very large 3...
Natera (NTRA) Signatera Data Shows Who Benefits From Chemotherapy After CRC Surgery
Natera's Signatera test was featured in new data on colorectal liver metastases, published in JAMA Oncology and presented at the ESMO GI congress. The results focus on how molecular residual disease status can guide adjuvant chemotherapy decisions in colorectal cancer patients. The findings provide evidence on which patients may benefit most from additional treatment after surgery, with implications for precision oncology and real world clinical practice. Natera, traded as NasdaqGS:NTRA, is...
Cathie Wood Dumps AMD, Doubles Down on Meta Stock
Cathie Wood's Latest Trade: Big Meta Bet, Fresh AMD Sell-Off
Natera (NTRA) Stock Still Looks Expensive After A Very Large Run
Natera stock has surged over the past three years, yet its valuation signals are split. A Discounted Cash Flow (DCF) intrinsic value estimate points to a sizeable discount to the current price, while market based multiples present a more expensive picture. Natera has delivered a very large 3 year return of 454.9%, which puts extra focus on whether the current price already reflects much of the good news. Progress with Signatera, including recent EU IVDR Class C certification and clinical...
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Cancer Blood Screen SPAC Merger Is Delayed by Test’s Results
Thursday was the day set for shareholders to approve the merger of special-purpose acquisition company Perceptive Capital Solutions with cancer screening firm Freenome. The resulting public company will compete with Guardant Health Grail and Natera in a market for cancer-detecting blood tests that they hope will eventually be worth more than $30 billion a year. The study shows Freenome’s updated SimpleScreen CRC test was somewhat less sensitive to cancers, overall, than Guardant’s Shield test, but the Freenome test was more sensitive to precancerous growths.
Frequently Asked Questions
Common investor questions about Natera, Inc.
Natera, Inc. (NTRA) is currently trading at $271.39. The RSI (14-day) is at 57.3, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $262.67 implies 3.2% downside from current levels. Volatility is moderate at 29.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Natera, Inc. (NTRA): The trailing P/E ratio is -166.50, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -1332.54, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 21.84. Price-to-Sales is 15.54. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 21 analysts covering NTRA, the consensus price target is $262.67. This represents a 3.2% downside from the current price of $271.39. The range spans from a low target of $193.00 to a high target of $310.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Natera, Inc. (NTRA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Natera, Inc. (NTRA) investors include: 1. Moderate volatility (29.6% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Natera, Inc.'s (NTRA) current debt and financial health profile: Total debt stands at $240.08M. The debt-to-equity ratio is 13.53, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 2.96, indicating strong short-term liquidity. The quick ratio is 2.70. The company holds $1.09B in cash and equivalents. Free cash flow is positive at $136.92M, providing a cushion for debt servicing and shareholder returns.